U.S. Capital Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,876	Closed	-$53.6K	–	1435
2022 Q4	$53.6K	Buy	+5,876	New	+$51.3K	﹤0.01%	865
2022 Q3	–	Sell	-10,226	Closed	-$77K	–	682
2022 Q2	$77K	Hold	10,226	–	–	﹤0.01%	652
2022 Q1	$96K	Sell	10,226 -2,700	-21%	-$22.5K	﹤0.01%	691
2021 Q4	$104K	Sell	12,926 -116,736	-90%	-$1.05M	﹤0.01%	699
2021 Q3	$1.26M	Buy	+129,662	New	+$1.21M	0.05%	344

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

U.S. Capital Wealth Advisors's TEVA Position: Q1 2023 in Review

U.S. Capital Wealth Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2023, closing a stake of 5,876 shares — an estimated $53.6K sold.

U.S. Capital Wealth Advisors first reported a position in TEVA in Q3 2021 and held it in 5 quarters. The position peaked at $1.26M in Q3 2021. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2023.

U.S. Capital Wealth Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
U.S. Capital Wealth Advisors sold 5,876 Teva Pharmaceuticals shares in Q1 2023, an estimated $53.6K.
U.S. Capital Wealth Advisors first reported a position in Teva Pharmaceuticals in Q3 2021 and held it in 5 quarters.
U.S. Capital Wealth Advisors's Teva Pharmaceuticals position peaked at $1.26M in Q3 2021.
438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2023.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2023, filed 11 May 2023.